ABAmit Bahl

Amit Bahl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amit Bahl has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Dn Sharma

    Department of Radiation Oncology, Delhi State Cancer Institute, New Delhi, India

    7 shared publications
  • Gk Rath

    Department of Radiation Oncology, Delhi State Cancer Institute, New Delhi, India

    7 shared publications
  • Arun Elangovan

    Department of Radiation Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India

    5 shared publications
  • Pk Julka

    Department of Radiation Oncology, Delhi State Cancer Institute, New Delhi, India

    5 shared publications
  • Roshan Verma

    Department of Otolaryngology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India

    5 shared publications
  • Satinder Kaur

    Department of Radiation Oncology, Post Graduate Institute of Medical Education & Research, Chandigarh, 160012, India

    5 shared publications

Latest Publications

  • Impact of Cochlear Radiotherapy Dose on Hearing Loss in Carcinoma Oropharynx Treated by Concurrent Chemoradiotherapy Using Simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB -VMAT)

    by A. Lokeswari, Amit Bahl, N. Banumathy, Jaimanti Bakshi, Satyawati Mohindra, Rijuneeta Gupta, Ghoshal Sushmita, Oinam Arun Singh, Ranjit Singh, Naresh Kumar Panda

    This study evaluates the impact of reduction of radiotherapy dose received by cochlea on hearing loss in oropharyngeal cancer patients treated by concurrent cisplatin chemoradiotherapy using simultaneous Integrated Boost Volumetric Modulated Arc Therapy (SIB-VMAT). Sixty ears were evaluated in this prospective non blinded randomized trial. The study group (n=30) was treated with concurrent chemoradiotherapy using Image Guided Radiotherapy with Simultaneous Integrated Boost-Volumetric Modulated Arc technique. The matched control group (n=30) received concurrent chemoradiotherapy using 3D conformal radiotherapy (3DCRT). Concurrent chemotherapy was given to all patients with injection Cisplatinum 100 mg/m2 on D1,22&43 along with radiotherapy. Baseline hearing evaluation was done using puretone, impedence and high frequency audiometry. The tests were repeated at 6 months follow up to evaluate hearing loss. The mean radiotherapy dose received by the right and left cochlea in the 3DCRT and SIB-VMAT techniques was 38.99±4.78 versus 6.97±6.09 Gy (mean±SD) (p=0.001) and 38.59±5.10 versus 6.79±5.76 Gy (p=0.001). At 6 months of follow up sensorineural hearing loss was observed in 66.7 versus 0% (p=0.001) and 86.7 versus 6.7% (p=0.001) in the right and left ear in the 3DCRT and SIB-VMAT groups.High risk PTV 66 volume more than 300 cc was associated with a higher risk of hearing loss with odds ratio of 6.05 (95% CI 0.54-67.53) and 4.41(95% CI 0.52-37.16) in right and left ear. Age more than fifty years was associated with significant hearing loss in the right ear with an odds ratio of 12.56 (95% CI 0.84-187.87) (p=0.02) and 7.38 (95% CI 0.74-73.59) for the left ear. The study shows that reduction in radiotherapy dose received by cochlea is an independent determinant in reducing ototoxicity in the setting of concurrent single agent cisplatin chemotherapy. High risk PTV volume more than 300 cc was associated with a significant increase in hearing loss and PTV 66 volume emerged as a predictive factor for treatment related hearing loss.


  • Pilot Evaluation of Perioperative High Dose Rate Brachytherapy in Head Neck Cancers

    by Amit Bahl, Naresh K. Panda, Roshan K. Verma, Vikas Sharma, Jerry J. John, Pramod Kumar, Arun S. Oinam, Gaurav Trivedi, Jaimanti Bakshi

    Perioperative high dose rate brachytherapy involves insertion of brachytherapy catheter over the tumor bed during surgical removal of disease followed by radiation in the postoperative period. It has applications in radiotherapy dose escalation or reirradiation and for extending the surgical margins. We report here initial results of treatment in five cases of locally advanced head and neck cancers.

  • Adenoid Cystic Cancer of the Lacrimal Gland: Management Aspects and Treatment Outcomes

    by Vishwa Jyoti Bahl, Amit Bahl

    Adenoid cystic carcinoma (ACC) of the lacrimal gland is the most common malignant epithelial tumor of the lacrimal gland. The biological behavior of these tumors is characterized by a slow growth with frequent nerve invasion but rare invasion of the neck nodes. Local extension intracranially with bone erosions is seen in locally advanced tumors. Distant metastasis to lungs bone and liver are commonly reported. Treatments using surgery and radiotherapy are generally preferred for adequate tumor control. However there is still no consensus on the best treatment approach.


  • Open Access

    Prognostic Value of HPV Infection Assessed by p16 Immunohistochemistry and the Influence of Tobacco Usage in Oropharyngeal Cancers: Real World Scenario

    by Sushmita Ghoshal, Chinna Babu Dracham, Archana Sundaram, Rajesh Kumar, Amanjit Bal, Ashim Das, Amit Bahl, Roshan Kumar Verma, Arun Elangovan

    To find if an association could be established between Human Papilloma Virus (HPV) infection and oropharyngeal cancers (OPCs) in a group of patients known to be regular users of tobacco, and to determine the impact of HPV status on clinical outcomes.Case records of 212 patients with AJCC-7 (The American Joint Committee on Cancer 7th edition) stages II–IVB non metastatic squamous cell carcinoma of the oropharynx treated using radical radiotherapy with or without chemotherapy during the years 2015–2018 were retrieved. Formalin-fixed, paraffin-embedded blocks from oropharyngeal biopsies were available for 177 patients and were evaluated for p16 expression by immunohistochemical (IHC) staining. More than 50% nuclear staining with or without cytoplasmic staining was considered HPV+ . The association between tobacco use and HPV, as well as the influence of HPV status on survival outcomes were assessed. p16 expression was found to be positive in 23(13%) patients. Significant association was found between chewable tobacco usage and HPV positivity (p = 0.051). The median follow up was 20.5 months (range: 3–80). 5-year Overall Survival was 43.4% and 29.8% (p = 0.044) in HPV+ and HPV− patients, respectively. Local control was significantly better in HPV+ patients (38.6% vs. 25.3%, p = 0.049). There was also a trend towards improved Disease-free Survival in HPV+ patients (31 months vs. 15 months, p = 0.078). Though less in prevalence among the Indian population, improved outcomes in HPV+ OPC patients and widely available IHC HPV assays signifies the routine implementation of p16 testing in day-to-day clinical practice.


  • Open Access

    Perioperative high dose rate brachytherapy in head and neck cancers: case report and review of clinical application

    by Amit Bahl, Roshan K Verma, Naresh K Panda, Arun S Oinam, Jerry R John, Satinder Kaur, Pramod Kumar, Sushmita Ghoshal, Gaurav Trivedi, Jaimanti Bakshi

    Perioperative high dose rate brachytherapy is a radiotherapy treatment technique which involves intraoperative insertions of brachytherapy catheters into the tumor bed during the surgical resection followed by treatment in the postoperative period. We report here two cases to highlight its use in the primary treatment and reirradiation of head and neck cancers.

    • 1 January 2019
      • Vol. 13  (1) , 33-39

    Analysis of volumetric and dosimetric changes in mid treatment CT scan in carcinoma nasopharynx: implications for adaptive radiotherapy

    by Amit Bahl, Arun Elangovan, Chinna Babu Dracham, Satinder Kaur, Arun Singh Oinam, Gaurav Trivedi, Roshan Verma, Naresh K. Panda, Sushmita Ghoshal

    Carcinoma of nasopharynx is a radiosensitive tumor and therapeutic response during radiation treatment can result in dosimetric variations in the delivered dose to the tumor and critical organs. This study was done to evaluate the volumetric and dosimetric changes seen in tumor tissue and organs at risk in a mid treatment planning scan and its implications for adaptive replanning. Twenty patients of locally advanced carcinoma nasopharynx were evaluated. All patients were started on treatment with a baseline treatment plan on SIB-VMAT. To evaluate volumetric and dosimetric changes during treatment, a mid treatment CT scan (MTS) was taken at the 17th fraction of treatment and compared with the baseline planning CT scan (BS). Adaptive treatment plans were generated on the MTS and further treatment was continued on the adaptive plans. The mean weight loss observed at the 17th fraction of treatment was 3.4 ± 2.6 kg(Mean±S.D). The mean neck diameter at C2 level was 14.19±1.02 and 13.29 ± 1.14 cm in the BS and MTS respectively (p=0.001). The GTV 70 volume showed a 29.16% volume loss. The mean doses received by the right and left parotids were 25.45±0.98 and 24.64±3.8 Gy in the baseline treatment plan and 33.21±11.29 (p=0.054) and 31.76±8.44 Gy respectively in the MTS (p=0.016) The mean weight loss showed a statistically significant correlation with increase in the right parotid(p=0.043) and left parotid doses(p=0.024). Weight loss during treatment combined with volume changes in target tissues mandate routine adaptive replanning while treating carcinoma nasopharynx.


  • Evaluation of Multimodality Management of Adenoid Cystic Carcinoma of the Head and Neck

    by Amit Bahl, Naresh Kumar Panda, Arun Elangovan, Jaimanti Bakshi, Roshan Verma, Satyawati Mohindra, Rijuneeta Gupta, Arun Singh Oinam, Satinder Kaur, R. K. Vashishta, et al.

    Adenoid cystic carcinoma is a relatively rare tumour arising from salivary glands of head and neck region. Surgery and radiotherapy form standard treatment modalities in the management of this tumor. In this analysis we present results of multimodality treatment in our cohort of patient. This retrospective analysis evaluated results of treatment in forty patients diagnosed with adenoid cystic carcinoma of the head and neck. Evaluation was done to identify prognostic factors affecting the disease free survival. A median disease free survival of 34 ± 2.42 (Median ± SE) versus 10 ± 5.45 months was seen in patients undergoing surgery followed by post operative radiotherapy versus radiotherapy alone (P = 0.01). A radiotherapy dose more than 60 Gy was associated with a better disease free survival compared with patients receiving less than 60 Gy (P = 0.01). Positive surgical margins and perineural invasion were associated with a poor treatment outcome (P = 0.02) Patients with c-kit positive status showed a poor local control rate (P = 0.05).


  • Open Access

    Evaluation of Reirradiation in Locally Advanced Head and Neck Cancers: Toxicity and Early Clinical Outcomes

    by Amit Bahl, Arun Singh Oinam, Arun Elangovan, Satinder Kaur, Gaurav Trivedi, Roshan Verma, Sudhir Bhandari, Sushmita Ghoshal, Naresh Kumar Panda

    Objectives. Locoregional recurrence is the predominant pattern of treatment failure in advanced head and neck cancers. Reirradiation is a useful modality to treat inoperable head and neck cancer patients with recurrent disease. The aim of the present study was to analyze the treatment toxicity and early clinical outcomes in patients undergoing reirradiation. Methods. Twenty patients of head and neck cancers with recurrences or second cancers were evaluated. Reirradiation was done using simultaneous integrated boost volumetric modulated arc therapy (SIB VMAT), intensity modulated radiotherapy (IMRT), or conventional radiotherapy using 6MV photons. Dose prescription ranged from 30 to 60 Gy in conventional fractionation. Results. Seventeen males and three females were evaluated in this analysis. The median age of patients under study was 56.5 years. At time of analysis 8 patients (40%) had a complete response, 7 patients (35%) had progressive disease, and 25% had partial response or stable disease. Grade III-IV mucositis, dermatitis, xerostomia, dysphagia, and trismus were seen in 20%, 20%, 50%, 35%, and 45% patients, respectively, during retreatment. Patients receiving a radiotherapy dose less than 45 Gy showed a higher incidence of progressive disease (p=0.01). The median disease-free survival for patients receiving reirradiation dose of ≥46 Gy was 19±3.3 months (median ± S Error) compared to 8±2.61 months for those with a dose prescription less than 45 Gy (p=0.03). At 18-month follow-up 26% of patients undergoing reirradiation were disease-free. Conclusions. Our results show improved tumor control using a prescription of doses ≥46 Gy in retreatment setting.


  • Open Access

    Evaluation of Acute Toxicity and Early Clinical Outcome in Head and Neck Cancers Treated With Conventional Radiotherapy and Simultaneous Integrated Boost Arc Radiotherapy

    by Amit Bahl, Arun S. Oinam, Satinder Kaur, Roshan Verma, Arun Elangovan, Sudhir Bhandari, Jaimanti Bakshi, Naresh Panda, Sushmita Ghoshal

    Chemoradiotherapy plays an important role in management of locally advanced head and neck cancers. This retrospective analysis was done to evaluate and compare acute toxicity profiles and early clinical outcomes in patients treated with conventional and arc techniques. Fifty-five patients of head and neck cancers were evaluated. Thirty patients received conventional radiotherapy with 6 MV or cobalt 60 and 25 patients were treated with simultaneous integrated boost-volumetric modulated arc radiotherapy (SIB-VMAT) with dose prescription of 66 - 70 Gy. Concurrent chemotherapy was given as cisplatin injection at 40 mg/m2 weekly or 100 mg/m2 thrice weekly. The incidence of grade 3-4 mucositis was 56% versus 83.3% with SIB-VMAT and conventional treatments (P = 0.026). The incidence of grade 2-3 xerostomia was 44% versus 80% (P = 0.006) in the two groups. Grade 2 dysphagia was seen in 40% versus 80% (P = 0.008) favoring the arc treatments. Seventeen patients undergoing arc treatment had complete response compared to 14 in the conventional group (P = 0.040). The median disease-free survival (median ± standard error) was 16 months (11 ± 1.987 months) in the conventional and arc groups (P = 0.073). SIB-VMAT shows a better toxicity profile and a trend towards better disease-free survival when compared to conventional radiotherapy in head and neck cancers.


  • Open Access

    Correction: Evaluation of Acute Toxicity and Early Clinical Outcome in Head and Neck Cancers Treated With Conventional Radiotherapy and Simultaneous Integrated Boost Arc Radiotherapy

    by Amit Bahl, Arun S. Oinam, Satinder Kaur, Roshan Verma, Arun Elangovan, Sudhir Bhandari, Jaimanti Bakshi, Naresh Panda, Sushmita Ghoshal

    [This corrects the article DOI: 10.14740/wjon1049w.].